Get the Stockscreener App
16.67
2.02%
0.33
After Hours:
16.67
Fulgent Genetics Inc stock is traded at $16.67, with a volume of 872.80K.
It is up +2.02% in the last 24 hours and down -29.24% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$16.34
Open:
$16.52
24h Volume:
872.80K
Relative Volume:
1.97
Market Cap:
$520.61M
Revenue:
$322.67M
Net Income/Loss:
$-61.63M
P/E Ratio:
-8.4817
EPS:
-1.9654
Net Cash Flow:
$-124.21M
1W Performance:
+10.11%
1M Performance:
-29.24%
6M Performance:
-24.33%
1Y Performance:
-2.23%
1-Day Range:
$16.52
$16.84
1-Week Range:
$14.92
$16.84
52-Week Range:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
16.67 | 510.31M | 322.67M | -61.63M | -124.21M | -1.9654 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc. - lincolnjournal.com
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent ... - Bluefield Daily Telegraph
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. - marketscreener.com
If You Invested $1,000 in Fulgent Genetics (FLGT) - Stock Titan
Aug Weekly: How is Fulgent Genetics Inc managing supply chain issues2026 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Fulgent Genetics, Inc.Common Stock (NQ: FLGT - The Chronicle-Journal
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (FLGT) Edition - Stock Traders Daily
Published on: 2026-03-19 03:58:12 - baoquankhu1.vn
Fulgent Genetics Completes $56.9M Acquisition of Bako Diagnostics and StrataDx to Expand Precision Medicine Services - Minichart
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx - BioSpace
Fulgent Genetics completes $56.9M pathology lab acquisitions By Investing.com - Investing.com Australia
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Fulgent Genetics Acquires Bako Diagnostics Assets, StrataDx for $56.9 Million - marketscreener.com
Fulgent Genetics completes $56.9M pathology lab acquisitions - Investing.com
Fulgent Genetics Expands Dermatology Footprint With Key Acquisitions - TipRanks
Fulgent Genetics (NASDAQ: FLGT) buys Bako Diagnostics and StrataDx - Stock Titan
Fulgent Genetics (NASDAQ:FLGT) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Fulgent Genetics, Inc. agreed to acquire Strata Pathology Services Inc. on December 22, 2025. A cash consideration will be paid by Fulgent Genetics, Inc. As part of consideration, an undisclosed value is paid towards None of Strata Pathology Services Inc. - marketscreener.com
Fulgent Genetics (FLGT) Stock Analysis Report | Financials & Insights - Benzinga España
Fulgent Genetics seeks new collaborations at Copenhagen ADPD2026 event - Traders Union
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha
Fulgent Genetics (NASDAQ: FLGT) CEO pays $10.7M to cancel share forward - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - FinancialContent
Fulgent Genetics (FLGT) Earnings Transcript - AOL.com
Aug Sectors: Should I hold or sell Fulgent Genetics Inc now2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
Fulgent Genetics Hits New 52-Week Low at $14.01 Amid Declining Performance - Markets Mojo
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Technical Analysis: Is Fulgent Genetics Inc a top pick in the sectorQuarterly Earnings Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fulgent Genetics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:FLGT) 2026-03-05 - Seeking Alpha
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - FinancialContent
FLGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulgent Genetics (FLGT) CSO has shares withheld to cover RSU taxes - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CEO has shares withheld for taxes - Stock Titan
Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused ExpansionWhat's Changed - Yahoo Finance
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating - marketscreener.com
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results - marketscreener.com
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress - simplywall.st
Fulgent Genetics (NASDAQ: FLGT) CFO has shares withheld for RSU taxes - Stock Titan
A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Fulgent Genetics (FLGT) Loss Widening In Q4 2025 Tests Bullish Growth Narratives - simplywall.st
Fulgent Q4 2025 slides: EPS beats, but customer loss drives stock plunge - Investing.com Australia
Fulgent Genetics (FLGT) Reports Strong Q4 Revenue Growth - GuruFocus
Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance - MarketBeat
Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Na - GuruFocus
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):